DNA methylation and Polycomb are key factors in the establishment of vertebrate cellular identity and fate. Here we report de novo missense mutations in DNMT3A, which encodes the DNA methyltransferase DNMT3A. These mutations cause microcephalic dwarfism, a hypocellular disorder of extreme global growth failure. Substitutions in the PWWP domain abrogate binding to the histone modifications H3K36me2 and H3K36me3, and alter DNA methylation in patient cells. Polycomb-associated DNA methylation valleys, hypomethylated domains encompassing developmental genes, become methylated with concomitant depletion of H3K27me3 and H3K4me3 bivalent marks. Such de novo DNA methylation occurs during differentiation of Dnmt3a W326R pluripotent cells in vitro, and is also evident in Dnmt3a W326R/+ dwarf mice. We therefore propose that the interaction of the DNMT3A PWWP domain with H3K36me2 and H3K36me3 normally limits DNA methylation of Polycomb-marked regions. Our findings implicate the interplay between DNA methylation and Polycomb at key developmental regulators as a determinant of organism size in mammals.
M
icrocephalic dwarfism represents a group of conditions of profound size reduction in humans. These single gene disorders are distinguished from other forms of dwarfism by severity and morphology. Growth is globally impaired prenatally and postnatally with proportionate scaling 1 . Reduced brain size in microcephalic dwarfism differentiates it from other forms of dwarfism and reflects an early developmental origin. We and others have discovered many microcephalic dwarfism genes that encode essential components of the cell cycle machinery, including replication licensing components [2] [3] [4] [5] and key mitotic proteins [6] [7] [8] . Mutations in these genes lead to reduced cell number and consequently reduced organism size 1 . As cell number is also the major determinant of size differences between mammals 9 and the molecular basis for many microcephalic dwarfism patients still remains to be defined, we performed wholeexome sequencing to identify novel genetic causes and inform understanding of size regulation.
Results
De novo mutations in DNMT3A causes microcephalic dwarfism. Whole-exome sequencing trio analysis of a microcephalic dwarfism family identified a de novo DNMT3A heterozygous mutation in the proband (NM_175629.2, c.988T> C, Fig. 1a ,b and Supplementary Table 1 ). This led to the replacement of a tryptophan residue with an arginine at codon 330 (p.Trp330Arg) in the highly conserved Pro-Trp-Trp-Pro (PWWP) domain of this DNA methyltransferase (Fig. 1c) . Next-generation sequencing of our patient cohort then identified an unrelated patient with the same heterozygous de novo missense variant in DNMT3A (c.988T> C p.Trp330Arg, Supplementary Table 1 ). This substitution was not present in the GnomAD 10 database, suggesting it to be absent from the general population. The two individuals were phenotypically similar, exhibiting substantial, proportionate reduction in head circumference and height (Supplementary Note, clinical synopsis). The shared clinical phenotype, in conjunction with independent de novo mutation of the same highly conserved residue, led us to conclude that these were pathogenic mutations. More recently, we ascertained a further microcephalic dwarfism patient with a de novo mutation in an adjacent codon (c.997G> A; p.Asp333Asn). Notably, the growth parameters of all three patients contrast markedly with those of previously reported patients with de novo germline missense and
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Articles NATuRe GeNeTicS truncating loss-of-function DNMT3A mutations 11, 12 who have the reciprocal phenotype of macrocephalic overgrowth Tatton-BrownRahman syndrome (TBRS, Fig. 1d ). As DNMT3A haploinsufficiency causes overgrowth 13 , this suggested that the c.988T> C and c.997G> A mutations were genetic gain-of-function mutations.
DNMT3A
W330R is stably expressed. To model the consequences of the p.Trp330Arg (W330R) substitution on DNMT3A stability, we engineered mouse embryonic stem cells (mESCs) homozygous and heterozygous for the orthologous substitution, W326R, using CRISPR/ Cas9-mediated homology-directed repair 14 .
Immunoblotting of these lines established that Dnmt3a
W326R is stably expressed. In contrast, mESCs homozygous for the overgrowth PWWP alterations p.Trp293del and p.Ile306Asn (p.Trp297del and p.Ile310Asn in human, respectively) had markedly lower Dnmt3a levels (Fig. 2a,  W293del and I306N ). We also generated recombinant wild-type (WT) and mutant human DNMT3A PWWP domains as glutathione S-transferase (GST)-fusion proteins. Whereas we could efficiently express and purify PWWP WT and PWWP W330R proteins, the overgrowth PWWP W297del and PWWP I310N proteins did not yield stable protein ( Supplementary Fig. 1a ). This supports the notion that the W330R substitution alters PWWP function distinctly from PWWP overgrowth alterations, which interfere with protein stability.
The W330R substitution impairs binding to methylated H3K36.
The PWWP domain of DNMT3A binds post-translationally modified histone H3 that has been trimethylated at lysine 36 (H3K36me3) 15, 16 . Tryptophan 330 is one of three aromatic amino acids that, along with an aspartate residue (Asp333), form an aromatic cage around the methylated lysine 17, 18 (Fig. 2b) . Structural modeling of the DNMT3A W330R substitution predicts that the arginine substitution substantially disrupts this interaction (interaction destabilization: 11.8 kcal mol -1 ).
To test this experimentally, we performed pull-down experiments of histone tail peptides using GST-PWWP fusion proteins. Although PWWP WT interacted with an H3K36me3-modified histone-tail peptide but not the corresponding unmodified peptide, we did not detect an interaction of the mutant PWWP W330R with H3K36me3 ( Fig. 2c,d ). To confirm this and assess whether the W330R substitution conferred an alternative binding specificity on the PWWP domain, a peptide array containing 384 unique and combinatorial histone tail modifications was probed with recombinant protein. Wild-type PWWP bound strongly to H3K36me3 and H3K36me2 as reported 15, 19 . However, under the same experimental conditions, PWWP W330R did not bind to any histone modification represented on the array ( Fig. 2e and Supplementary Fig. 1b) .
The second substitution, p.Asp333Asn (D333N), is located at the aspartate residue that forms part of the cage surrounding H3K36me2 or H3K36me3 (Fig. 2b) . As substitution of this residue is known to abrogate H3K36me2 and H3K36me3 binding 15 , we conclude that both the W330R and D333N substitutions likely impair binding of DNMT3A to methylated H3K36.
Increased DNA methylation at key developmental genes. The N-terminal and ATRX-DNMT3-DNMT3L (ADD) domains of DNMT3A also mediate chromatin interactions 20, 21 . Therefore, the DNMT3A W330R and DNMT3A D333N proteins would still bind chromatin but have altered binding specificity. This in turn could modify the pattern of DNA methylation in patient cells. We therefore assessed the genome-wide distribution of DNA methylation in patient-derived fibroblasts using Illumina Infinium MethylationEPIC beadchips. Unsupervised hierarchical clustering established that dermal primary fibroblasts from DNMT3A W330R/+ microcephalic dwarfism patients had similar DNA methylation profiles, which were significantly distinct from fibroblasts from healthy subjects ( Fig. 3a , P < 0.001 for each group). 1,878 differentially methylated regions (DMRs) were common to both patients ( Fig. 3b and Supplementary Fig. 2 ). Consistent with altered genomic targeting of DNMT3A W330R , the majority of DMRs were hypermethylated relative to controls (n = 1,140, Fig. 3b ,c and Supplementary Table 2) . Notably, the same regions of increased DNA methylation were also present in DNMT3A W330R/+ patient peripheral blood leukocytes (PBLs), indicating this to be a reproducible signature and not a consequence of in vitro culture 22 ( Fig. 3b,c) . Furthermore, the same hypermethylated DMRs were also evident in patient P3's PBLs (Supplementary Fig. 3 ). In contrast, DMRs hypomethylated in fibroblasts were not observed in patient PBLs (n = 738; Supplementary 2 ). The heterozygous de novo c.997G> A mutation results in substitution of an aspartic acid residue (patient 3). c, Both residues are conserved in vertebrates and replaced with a physiochemically dissimilar residue: arginine (W330R) and asparagine (D333N), respectively. Sequence alignments, Clustal Omega. d, The W330R and D333N alterations cause extreme growth failure and microcephaly (red diamonds, n = 3 independent patients), in direct contrast to DNMT3A overgrowth patients (grey circles, n = 13 and n = 12 patients, respectively, for height and head circumference (OFC) W326R protein, containing the orthologous substitution to W330R, is stably expressed, in contrast to corresponding overgrowth PWWP mutants (W293del, I306N). Immunoblotting of cell lysates from CRISPR/Cas9 genome-edited mESCs. Multiple independent cell lines, with genotypes as indicated. Representative of n = 3 (wildtype, W326R lines) and n = 2 (W293del, I306N) independent experiments. Immunoblots are cropped. b, Structural modelling of the PWWP domain predicts the p.Trp330Arg substitution to disrupt interaction with H3K36me3. The highlighted amino acids (blue) form a cage that binds trimethylated Lys36 (purple). The amino acids altered in microcephalic dwarfism patients (tryptophan at codon 330 and aspartate at codon 333) are labeled in red. Backbones of PWWP and histone H3 N-terminal tail depicted in grey and pink, respectively. Fig. 1b ).
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Figs. 2a,b and 3b,c and Supplementary Table 3 ). DNMT3A
W330R hypermethylated DMRs were not evident in DNMT3A overgrowth patient PBLs (Fig. 3b,c) , and were also absent from pericentrin (PCNT)-null patient fibroblasts, indicating they were not a general consequence of microcephalic dwarfism (Supplementary Fig. 2c ).
Gene ontology analysis for the genes located closest to the hypermethylated DMRs demonstrated a marked association with transcription factors and developmental processes ( Fig. 3d and Supplementary th percentile; whiskers, full data range; center line, median; ∆ %mCpG, percent change of methylation relative to mean of control. P value, two-sided, paired Wilcoxon rank sum tests for mean of control probes versus mean patient probes. d, Gene ontology analysis of genes associated with hypermethylated DMRs. Top ten significant hits shown. Color indicates Benjamini-Hochberg adjusted FDR significance level, genes associated with DMR probes (n = 907 genes) versus genes associated with all probes on the array (n = 18,159), two-sided Fisher's exact test. e, Examples of DNA-binding factors and morphogens associated with DMRs. f, Representative genome browser views of hypermethylated DMRs demonstrating increased DNA methylation at key developmental genes in microcephalic dwarfism patient samples. All tracks scaled 0-100%. mCpG, DNA methylation; CGI, CpG islands.
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DMR gene list (Fig. 3e) . Visual inspection of the DMRs established these regions to contain CpG islands and encompass genomic regions surrounding these developmental genes (Fig. 3f) .
Hypermethylated Polycomb-marked DNA methylation valleys. To understand the genomic context of the hypermethylated DMRs, we investigated their chromatin state by intersecting the DMRs with existing ChromHMM annotations for normal human lung fibroblasts 23 . The DMRs were significantly enriched for 'poisedpromoter' and 'Polycomb-repressed' ChromHMM categories (Fig. 4a) , both of which are associated with Polycomb repressive complexes (PRCs). To directly address whether these hypermethylated DMRs were Polycomb-marked regions in dermal primary fibroblasts, we next performed chromatin immunoprecipitation and sequencing (ChIP-seq) for H3K27me3, the epigenetic signature of Polycomb repressive complex 2 (PRC2) 24, 25 . We observed significant enrichment for control fibroblast H3K27me3 peaks at DMR sites (P < 2.2 × 10 −16
; Fig. 4b-d) , confirming them to be normally marked by H3K27me3.
Notably, regions of increased DNA methylation in patient cells were not confined to CpG islands and often extended over tens of kilobases of genomic sequence (Fig. 3f) . Their extent and location were reminiscent of ordinarily hypomethylated domains that have been termed DNA methylation valleys (DMVs) 26, 27 , DNA methylated canyons 28 or broad nonmethylated islands 29 . These are evolutionary conserved regions that are often associated with Polycomb-regulated developmental genes. Subsequent analysis confirmed a significant overlap between genes within reported DMVs 26 and genes associated with DNMT3A W330R/+ hypermethylated DMRs (P = 8.3 × 10 −170
; Fig. 4e ).
Comparison of H3K27me3-marked DMVs in control fibroblasts with those lacking H3K27me3 established that the Polycomb-associated DMVs were specifically hypermethylated in patients (P = 9.6 × 10 −83 ; Fig. 4f-h ). Subsequent H3K4me3 ChIPseq showed that hypermethylated DMVs also contained H3K4me3 peaks ( Fig. 4f) , consistent with ChromHMM poised-promoter predictions (Fig. 4a) . DMVs without Polycomb marks exhibited higher levels of H3K4me3 (Fig. 4g,i) , consistent with transcriptionally active loci.
In DNMT3A W330R/+ fibroblasts, H3K27me3 levels were reduced at hypermethylated DMRs and H3K27me3-marked DMVs (Fig. 4f,g and Supplementary Fig. 4a-f ). However, levels of the H3K27me3 methyltransferase EZH2 were normal in patient fibroblasts, and total cellular levels of H3K27me3-marked histones were unchanged when assessed by mass spectroscopy (Supplementary Fig. 4g-i) . Therefore, reduction in H3K27me3 was probably the result of DNMT3A-mediated DNA methylation inhibiting PRC2 binding and activity 30, 31 . H3K4me3 levels were also reduced at hypermethylated DMRs and H3K27me3-marked DMVs ( Supplementary  Fig. 5a -e) significantly more than at other H3K4me3 peaks in the genome, consistent with this reduction also being a secondary consequence of DNA hypermethylation.
We therefore concluded that the W330R alteration is associated with hypermethylation of Polycomb-marked DMVs in patient cells, affecting bivalent histone marks and modifying the chromatin state at key developmental regulators.
H3K36me3 and H3K27me3 histone modifications are usually mutually exclusive 32, 33 , and strongly negatively correlated genomewide 34 . To confirm that this was also the case for DMRs and DMVs, we performed H3K36me3 ChIP with reference exogenous genome (ChIP Rx-seq), and indeed found that few H3K36me3 ChIP-seq reads were present in DMVs in control and patient cells, with no enrichment over ChIP input seen ( Supplementary  Fig. 6a,b) . Furthermore, hypermethylated DMRs in both control and patient fibroblasts were substantially depleted for H3K36me3 ChIP-seq peaks when compared to all Infinium array probe sites ( Supplementary Fig. 6c ).
Hypermethylation differentiation of DNMT3A
W326R mESCs. As large-scale de novo DNA methylation occurs during early embryogenesis 35 , we reasoned that the increased methylation detected in patient fibroblasts and leukocytes probably had developmental origins. We addressed this possibility using the previously generated Dnmt3a W326R mESCs containing the W330R-orthologous mouse alteration (Fig. 2a) . However, bisulfite sequencing of the promoter CpG islands of Hoxc13, Sox1 and Foxa1 (loci we had established to have increased methylation in patient cells) demonstrated similarly low levels of DNA methylation in wild-type, DNMT3A
W326R/+ and DNMT3A W326R/W326R mESCs ( Fig. 5a and Supplementary Fig. 7a ,b). Nevertheless, upon differentiation to embryoid bodies, DNA hypermethylation became evident in DNMT3A W326R/+ and DNMT3A
W326R/
W326R cells relative to controls (Fig. 5b ). To exclude skewing of lineage fate in embryoid bodies as a confounding explanation for altered methylation, we also performed directed differentiation of mESCs to . All, all probes on the array (n = 403,348 probes). Hyper-DMRs, probes within hypermethylated DMRs (n = 10,871). P value, two-sided Fisher's exact test. d, Venn diagram displaying overlap of hypermethylated DMRs (n = 1,140) with H3K27me3 peaks (n = 3,815) in controls. P value, two-sided Fisher's exact test. e, Genes associated with hypermethylated DMRs (n = 907 genes) significantly overlap genes associated with DMVs (n = 1,358). Two-sided Fisher's exact test, genes associated with hypermethylated DMRs versus all genes represented on array. f, Increased methylation is distributed across H3K27me3 regions, but excluded from H3K4me3 peaks. Representative genome browser views. For all tracks: DNA methylation (magenta, scale 0-100%), H3K27me3 (green, scale 0-4 scaled read counts per 10 7 reads), H3K4me3 (yellow, scale 0-8 scaled read counts per 10 7 reads) in control (C1 and C2) and patient (P1 and P2) dermal fibroblasts. DNA methylation data for SOX1 and FOXA1 (Fig. 3f) . This also demonstrated increased methylation in DNMT3A W326R cells (Fig. 5c) . Furthermore, reduced representation bisulfite sequencing (RRBS) 37 established that such methylation occurred at many Polycomb-marked loci in neurally differentiated cells (Fig. 5d,e) . We detected 342 hypermethylated DMRs in DNMT3A W326R/W326R cells relative to wild-type controls (Supplementary Table 5 ). These regions were significantly enriched for H3K27me3 ChIP-seq peaks derived from a wild-type neural-progenitor differentiation data set 38 , Fisher's exact test; Fig. 5f ). Therefore, we conclude that the W326R substitution causes methylation at Polycomb-marked developmental genes from early stages of cell fate specification and differentiation in vitro. W330R/+ fibroblasts. We found significant downregulation of transcription of genes associated with hypermethylated DMRs, whereas transcript levels at hypomethylated DMRs were unchanged ( Fig. 5g and Supplementary Fig. 8a-c) . We reasoned that many of the DMR-associated genes were transcription factors that would consequently perturb developmental transcriptional networks. Differentiation is impaired in Dnmt3a-deficient NPCs and hematopoietic stem cells, with enhanced expression of multipotency genes and decreases in differentiation genes 31, 39, 40 . As W326R is a gain-of-function alteration, we postulated that a reciprocal transcriptional phenotype would be evident in Dnmt3a W326R/ W326R NPCs. Accordingly, we examined two gene sets representing genes that are, respectively, upregulated and downregulated during differentiation of mESCs to terminally differentiated neurons 38 .
In line with our expectation, Dnmt3a
W326R/W326R NPCs demonstrated a transcriptional bias toward expression of neurogenic genes at the expense of genes normally expressed in the pluripotent state (Fig. 5h,i) . This suggests that hypermethylation of DMVs and DMRs could lead to a skewing of stem or progenitor cells toward differentiation away from self-renewal.
Dnmt3a
W326R/+ mice have reduced brain size and body weight. Finally, we generated a Dnmt3a W326R/+ mouse using CRISPR/Cas9-mediated homology-directed repair ( Supplementary Fig. 9a,b) to provide an in vivo model. Recapitulating the patient growth restriction phenotype, Dnmt3a W326R/+ mice were viable, healthy and morphologically unremarkable, but were proportionately small with significantly reduced body and brain weight (Fig. 6a-c and Supplementary Fig. 9c,d) . Furthermore, bisulfite sequencing of cerebral cortex and liver provided in vivo confirmation of hypermethylation at Polycomb-regulated regions, with substantial methylation observed at the Hoxc13 and Sox1 loci in Dnmt3a W326R/+ mice ( Fig. 6d and Supplementary Fig. 9e ). RRBS analysis confirmed that genome-wide, NPC hypermethylated DMRs were hypermethylated in the Dnmt3a W326R/+ mouse cortex ( Supplementary Fig. 9f-h ). 32, 33 ). This limits availability of free DNMT3A to bind at other locations. When the PWWP interaction with H3K36me2 and H3K36me3 is disrupted, sufficient free DNMT3A is available to methylate genomic DNA at DMVs. Enzymatic activity of DNMT3A and DNA methylation impair PRC2 chromatin binding 30, 31 , leading to secondary loss of H3K27me3. Notably, the long isoform of DNMT3A (DNMT3A1) localizes to the edge of Polycomb domains 21, 43 . When altered through mutation, it is therefore well placed to methylate these regions. DNMT3A1 is also the major isoform expressed after ESC differentiation 21 , potentially explaining timing of hypermethylation. Filled circles, methylated CpG (mCpG); open circles, unmethylated CpG; diamonds, H3K36me2-and H3K36me3-modified histones. PWWP interaction mutations (PWWPmut).
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Discussion
Here we report widespread DNA hypermethylation at Polycombregulated regions resulting from a gain-of-function mutation in DNMT3A. As such genomic regions contain key developmental genes, classical patterning defects might be expected, but the DNMT3A W330R alteration instead causes an extreme growth disorder. Our findings suggest that the DNMT3A PWWP domain limits DNA methylation at Polycomb-regulated regions. DNMT3A has been previously shown to counter H3K27 trimethylation in vivo, with wild-type (but not catalytically dead) DNMT3A opposing PRC2 binding in neural stem cells 31 . In patient cells, it is therefore probable that altered binding specificity of DNMT3A W330R leads to it methylating Polycomb-associated DMRs and DMVs, with a secondary reduction occurring in H3K27me3 due to impaired binding of PRC2 to methylated DNA 30, 31 . Biochemically, binding to H3K36me2 and H3K36me3 is abrogated in the PWWP W330R mutant. How then could this impaired interaction with H3K36me2 and H3K36me3 connect with DNA methylation of H3K27me3 regions? We favor a model in which widespread distribution of H3K36me2 and H3K36me3 leads to wild-type DNMT3A being targeted to many genomic sites. This then limits DNMT3A's availability to nonpreferred sites such as Polycomb-associated regions (Fig. 6e) . Consistent with this model, we see low levels of H3K36me3 at DMRs and DMVs, which are explained by H3K36me2 and H3K36me3 rarely coexisting with H3K27me3 on histones 32, 33 . Additionally, genome-wide, H3K36me3 is strongly negatively correlated with H3K27me3, and low levels of H3K36me2 are correlated with increased H3K27me3 (ref. 34 ). Furthermore, H3K36me2 is actively removed by KDM2A from unmethylated CpG regions 41 , and Nsd1-mediated H3K36me2 methylation has recently been shown to restrict deposition of H3K27me3 (ref. 34 ). In our model, we propose that disruption of interactions of PWWP with H3K36me2 and H3K36me3 in patient cells would increase availability of DNMT3A W330R to interact with DNA in Polycomb regions (Fig. 6e) , increasing the possibility of DNA methylation and consequently impairing PRC2 binding and Polycomb-domain integrity. Alternative explanations are also possible. For instance, the interaction of PWWP WT with H3K36me2 and H3K36me3 may normally be required for enzymatic activity, whereas DNMT3A W330R may be permissive for DNA methylation without the interaction, or the PWWP domain may mediate nonhistone interactions that are critical to restrict it from Polycomb-marked loci. Further studies, including assessment of DNMT3A W330R localization by ChIP-seq to determine genomic distribution, will be important in distinguishing between these possibilities. Nonetheless, our findings establish the DNMT3A PWWP domain as a factor countering methylation of key developmental loci, one that may act alongside Tet enzymes 42, 43 and lysine demethylase 2B (KDM2B, also known as FBXL10) 44 to ensure their hypomethylation.
Previously identified microcephalic dwarfism genes impair cell proliferation to reduce cell number and organism size 1 , so how might this mutation in DNMT3A act? Both DNA methyltransferases and Polycomb can impart heritable transcriptionally repressive epigenetic marks. However, whereas DNA promoter methylation is considered to stably silence genes 45 , Polycomb repression is potentially reversible, maintaining plasticity of gene expression and enabling robust switching to gene activation in response to developmental cues 46, 47 . Dnmt3a loss in hematopoietic stem cells leads to expanded stem cell numbers at a cost to differentiated progeny 39 . Likewise, Dnmt3a-null neural stem cells have markedly reduced neurogenic potential 31 . Conversely, loss of the PRC2 H3K27me3 methyltransferase, Ezh2, from cortical progenitors impairs self-renewal, promoting premature neuronal differentiation 48 , and here we observe a transcriptional bias away from pluripotency toward differentiation in Dnmt3a W326R/W326R NPCs (Fig. 5) . Hence, gain-of-function DNMT3A mutations might increase cellular differentiation, leading to premature depletion of stem and/or progenitor cell pools, and reduce final cell numbers in tissues and consequently organism size ( Supplementary Fig. 8d ). Like DNMT3A, haploinsufficiency of H3K36 methyltransferases NSD1 and SETD2 causes macrocephalic overgrowth 13, 49, 50 . Mutations in genes encoding EZH2 and EED subunits of Polycomb complexes also cause overgrowth [51] [52] [53] , and PHC1 mutation results in microcephalic dwarfism 54 . Although DNA methylation and Polycomb repression are thought of as mutually antagonistic and exclusive processes at specific loci, our findings linking H3K27, H3K36 and DNA methylation suggest a yet to be defined common developmental mechanism for these syndromes. Furthermore, given that NSD1, DNMT3A and EZH2 are both quantitative trait loci for height and somatically mutated in cancer 55, 56 , the interplay between Polycomb and DNA methylation has wider relevance, both to neoplastic processes and to physiological regulation of human size, that warrants further investigation.
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Methods
Research subjects. Genomic DNA from affected children and family members was extracted using standard protocols. Informed written consent was obtained from all participating families. The study was approved by the Scottish Multicentre Research Ethics Committee (05/MRE00/74) and the Institutional Review Board of Cincinnati Children's Hospital Medical Center (protocol 2014-5919). All relevant ethical regulations were followed. Genotypes of TBRS patients were as follows: O1, DNMT3A heterozygous c.1936G> C p.Gly464Arg; O2, DNMT3A heterozygous c.2086del p.Gln696ArgFsTer9.
Exome sequencing. Exome sequencing of patients P1 and P3 was performed by Edinburgh Genomics and Cincinnati Children's Hospital Sequencing Core Facility, respectively, as described 59, 60 . DNA of patient P2 was sequenced by Illumina MiSeq using a custom targeted capture (SureSelect, Agilent Technologies) targeting DNMT3A and other primordial dwarfism and microcephaly genes. Confirmatory Sanger sequencing was performed on all affected individuals and their parents. Primers are listed in Supplementary Table 6 . For further details, see Supplementary Note.
Cell culture. Primary fibroblast cell lines were maintained at 3% O 2 in DMEM (Life Technologies) supplemented with 10% FBS and 5% penicillin-streptomycin antibiotics or in AmnioMAX-C100 (Life Technologies). HeLa cells, a gift from G. Stewart (Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham) originally obtained from American Type Culture Collection, were maintained in DMEM (Life Technologies) supplemented with 10% FBS and 5% penicillin-streptomycin antibiotics. E14 Tg2a IV mESCs were cultured on 0.1% gelatin-coated dishes and maintained in Glasgow's minimum essential medium (GMEM; Life Technologies) supplemented with 10% FBS (HyClone), 1 mM sodium pyruvate (Sigma); 1× MEM nonessential amino acids (Sigma), 2 mM l-glutamine, 5% penicillin-streptomycin antibiotics, 0.001% β -mercaptoethanol (Sigma) and leukemia inhibitory factor. For details of differentiation protocols, see Supplementary Note.
Generation of CRISPR/Cas9-edited mESCs. Guide RNAs were designed using the optimized CRISPR design web tool (http://crispr.mit.edu/) with corresponding oligonucleotides cloned into pSpCas9(BB)-2A-GFP or pSpCas9n(BB)-2A-GFP (gift from Feng Zhang, Addgene Plasmids pX458:#48138, pX461:#48140) 14 . Singlestranded DNA oligonucleotide (ssODN, IDT Ultramers) repair template sequences for homology-directed repair are listed in Supplementary Table 6 . Two independent CRISPR/Cas9 strategies were used to generate the Trp326Arg mutation in the clones used in this study, each using different guide RNAs (gRNAs), and either Cas9-nickase (nCas9) or wild-type Cas9, respectively. Vectors containing gRNA sequences were transfected together with single-stranded DNA oligonucleotides using FuGENE HD transfection reagent (Promega). Green fluorescent proteinpositive (GFP + ) cells were selected by FACS (FACSAriaII, FACSDiva Software Version 6.1.3, Becton-Dickinson) 48 h after transfection and plated at clonal density. Individual colonies were grown up and validated by Sanger sequencing.
Immunoblot analysis and antibodies. Whole-cell extracts for mESCs, human primary fibroblasts and HeLa cells were obtained by sonication in UTB buffer (8 M urea, 50 mM Tris, pH 7.5, 150 mM β -mercaptoethanol), analyzed by SDSpolyacrylamide gel electrophoresis (SDS-PAGE) using 4-12% NuPage Bis-Tris protein gels (Life Technologies) and transferred onto nitrocellulose membrane. Immunoblotting was performed using antibodies to Dnmt3a (Novus Biologicals, NB120-13888; 1:500), EZH2 (Cell Signaling, 5246S; 1:1,000) and actin (Sigma, A2066; 1:5,000). Images were acquired with ImageQuant LAS 4000. Uncropped images are shown in Supplementary Fig. 11 . RNA interference. EZH2 was targeted with 40 nM of an ON-TARGETplus Human siRNA SMARTpool (L-004218-00-0005, Dharmacon) and cells were harvested 48 h after transfection with RNAiMAX (Thermo Fisher).
Reverse transcription PCR and RNA sequencing. RNA was extracted using the RNeasy kit (QIAGEN) according to manufacturer instructions with DNAse I (QIAGEN) treatment. cDNA was generated using SuperScript III Reverse Transcriptase (Invitrogen) and random primers (Promega). PCR primers are listed in Supplementary Table 6. For RNA-seq, random primed cDNA from poly(A) selected RNA was converted into an Illumina sequencing library and single-end 50-base pair (bp) reads were generated on an Illumina HiSeq machine (GATC Biotech).
RNA-seq data were aligned to the genome using bowtie 2 (version 2.3.1). For further data processing details, see Supplementary Note. Alignment statistics are provided in Supplementary Table 7 , and summaries of the data are in Supplementary Fig. 8a,b. Structural modeling. The impact of p.Trp330Arg on the interaction with H3K36me3 was modeled with FoldX 61 using the crystal structure of the DNMT3B PWWP domain bound to H3K36me3 (PDB ID: 5CIU). The change in interaction energy caused by the equivalent Trp263Arg substitution in DNMT3B was calculated with the AnalyseComplex function. The H3K36me3 binding site is highly conserved between DNMT3A and DNMT3B, including full conservation of all the aromatic residues involved in binding highlighted in Fig. 2 , suggesting that p.Trp330Arg would also disrupt the interaction.
Generation of recombinant PWWP protein.
PWWP domain of DNMT3A was expressed in Escherichia coli and purified using standard methods, as documented in Supplementary Note.
Histone peptide pull-downs. Purified recombinant GST-PWWP fusion protein (20 µ g) and 2,000 pmol of histone H3 biotinylated peptides (AnaSpec peptides; AS-64440 and AS-64441) were diluted in interaction buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM EDTA, 0.1% Triton X-100 freshly supplemented with 0.5 mM dithiothreitol, 0.2 mM phenylmethyl sulfonyl fluoride and 1× protease inhibitor cocktail, Roche) 15 . Reactions were incubated overnight under rotation at 4 °C. MyOne T1 streptavidin beads (Life Technologies) were added to the reactions and rotated for 4 h at 4 °C, followed by three washes with interaction buffer. Sample loading buffer (20 µ l; 50 mM Tris, pH 6.8, 20% glycerol, 20% SDS, 625 mM β -mercaptoethanol, bromophenol blue) was added to beads and boiled for 5 min, and eluted proteins were separated on 15% SDS-PAGE and visualized with Coomassie blue R250.
Peptide arrays. Peptide arrays were processed according to manufacturer instructions for the MODified Histone Peptide Arrays (Active Motif). In brief, arrays were blocked and washed with buffers provided. Either 10 nM or 100 nM wild-type or W330R DNMT3A GST-tagged PWWP protein was diluted in interaction buffer (100 mM KCl, 20 mM HEPES, pH 7.5, 1 mM EDTA, 0.1 mM dithiothreitol, 10% glycerol) 15 and incubated overnight at 4 °C on an orbital shaker. Protein-peptide interactions were detected with an antibody to the GST tag (GE Healthcare 27-4577-01; 1:5,000) with subsequent enhanced chemiluminiscent (ECL)-based detection. c-Myc was detected with c-Myc mouse monoclonal antibody (1:2,000, Active-Motif). Images were acquired using ImageQuant LAS 4000.
Infinium MethylationEPIC BeadChip assay. Fibroblast genomic DNA was extracted using the DNeasy Blood & Tissue Kit (QIAGEN). DNA was bisulfite converted using the EZ DNA Methylation kit (Zymo Research, Infinium assay protocol). Infinium MethylationEPIC BeadChip assay (Illumina) was performed according to manufacturer instructions by Edinburgh Wellcome Trust Clinical Research Facility (WTCRF). The Bioconducter package minfi (version 1.22.1) was used to process raw Infinium idat files (ssNoob method) 62, 63 . For further details, see Supplementary Note. Overall summaries of Infinium methylation data are in Supplementary Fig. 10a,b,d .
Chromatin immunoprecipitation and sequencing. Cross-linked chromatin immunoprecipitation was adapted from previous publications 64, 65 , and is further detailed in Supplementary Note. For H3K27me3, single-end 50-bp reads were generated on an Illumina HiSeq machine (GATC Biotech). For H3K4me3, H3K36me3 ChIP-Rx and H3K27me3 ChIP-Rx, single-end 75-bp reads were generated on an Illumina NextSeq 550 machine (Edinburgh WTCRF).
ChIP-seq read quality assessment and alignment were performed as for RNAseq. For ChIP Rx-seq, reads were aligned to a combination of the hg19 and dm6 genomes using the same settings. Multimapping reads were excluded as for RNAseq. Additionally, PCR duplicates were excluded using SAMBAMBA (version 0.5.9) 66 . Sequencing statistics are in Supplementary Histone acid extraction and histone post-translational modification detection by mass spectrometry. Histones were acid extracted as described 32 with minor modifications, and liquid chromatography mass spectrometry/mass spectrometry analyses were performed on an Orbitrap Fusion Lumos coupled to Dionex Ultimate3000RSLCnano UHPLC system. For further details, see Supplementary Note. Bisulfite PCR sequencing. Genomic DNA was isolated using the DNeasy Blood & Tissue Kit (QIAGEN) or phenol-chloroform extraction. DNA (250-500 ng) was bisulfite converted with the EZ DNA Methylation-Lightning kit (Zymo Research) according to manufacturer instructions. Converted DNA was eluted twice in 10 µ l elution buffer. Bisulfite PCR primer sequences are provided in Supplementary  Table 6 . Products were amplified using FastStart PCR Master Mix (Roche), purified using the QIAquick PCR purification kit (QIAGEN) and subcloned into pGEMTeasy (Promega). Individual bacterial colonies were Sanger sequenced using M13 sequencing primers and analyzed using BISMA 67 , and results were formatted with the BiQ Analyzer Diagrams tool 68 . In two independent experiments of NPC and embryoid body differentiation, the following cell lines were used: for embryoid body experiments, WT3, hom2 (n = 2); WT1, hom3, het (n = 1); for NPC, WT1, hom2, hom3, het (n = 2); WT2, WT3, hom1 (n = 1).
Reduced representation bisulfite sequencing. Genomic DNA was isolated with DNeasy Blood & Tissue Kit (QIAGEN) or Nucleon BACC2 Genomic DNA Extraction Kit (illustra) and quantified by Qubit (Invitrogen). DNA from mouse Articles NATuRe GeNeTicS cortex samples was concentrated using Agencourt AMPure XP technology. 200 ng of purified DNA samples (for NPC differentiation, DNA from experiment depicted in Fig. 5c ; for mouse cortexes, in Fig. 6d and Supplementary Fig. 9e) were processed using the Ovation RRBS Methyl-Seq system kit (NuGen Technologies) according to instructions with modifications documented in Supplementary Note. RRBS was aligned and processed using Bismark (v0.16.3) 69 . Processed RRBS files were assessed for conversion efficiency based on the proportion of methylated reads mapping to the λ genome spike-in (> 99.5% in all cases, Supplementary Table 9 ) and processed in R to call DMRs. Alignment statistics are provided in Supplementary Table 9 . BigWigs were generated from RRBS data using CpGs with coverage ≥ 5. BigWigs for patient 3 and control 3 were generated only from CpGs with coverage ≥ 5 in both samples to facilitate visual comparison (shown in Supplementary Fig. 3d ). Overall summaries of RRBS data are shown in Supplementary Fig. 10c ,f-h. Mean methylation in each sample was calculated as the weighted mean across all CpGs observed on autosomes irrespective of coverage (methylated coverage/total coverage).
Generation of Dnmt3a
W326R mice. A template for in vitro transcription was prepared by PCR using the pX458-based plasmid containing the Dnmt3a-targeting gRNA sequence, a T7-tagged gRNA-specific forward primer, and a universal reverse primer (see Supplementary Table 6 ). PCR product was purified by QIAquick PCR Purification (QIAGEN) and gRNA was produced by in vitro transcription (NEB HiScribe T7 High Yield RNA Synthesis kit) using 1 µ g of PCR product, and purified using the RNeasy Mini Kit (QIAGEN). Transgenic mice were generated by cytoplasmic injection of gRNA (25 ng µ l ) into B6CBAF1/J single-cell embryos. All resulting pups were screened by PCR amplification and Sanger sequencing of the targeted region (for primer sequences, see Supplementary Table 6 ). F0 males were crossed with CD-1 females to establish germline transmission. F1 Dnmt3a W326R/+ males were crossed with CD-1 females and F2 offspring were used for phenotyping and tissue collection (investigators were blinded to genotypes). Mouse studies were approved by the University of Edinburgh animal welfare and ethical review board and conducted according to UK Home Office regulations under a UK Home Office project license.
Statistical analysis. Statistical testing was performed using R version 3.4.2 and GraphPad PRISM 6. Tests used are indicated in figure legends. All tests were two-sided unless otherwise stated. Further details of specific analyses provided in relevant methods sections are described below and in Supplementary Note.
Hierarchical clustering.
Clustering was performed on processed Infinium Beta probe values using R (Pearson correlation distance and Ward method). Cluster significance was tested using the CRAN package pvclust (version 2.0.0).
Differentially methylated region identification. Windows of five contiguous probes or CpGs were used to identify DMRs for Infinium and RRBS data, respectively. For Infinium arrays, DMRs were called on the basis of ≥ 3 probes in a window having a difference in β -value of at least 0.1 between each individual patient sample and each of the two control fibroblast lines, changed in the same direction, and with no CpG ≥ 1,000 bp from its neighbors in the window. For this analysis, we also only considered probes showing the same difference in both the patient 1 replicates. Overlapping or contiguous DMR windows were merged. For enrichment analyses, the set of DMR probes was compared to a genome-wide background control set of 'all' probes, derived from genomic regions spanning genomically contiguous probes that fulfilled the same distance threshold criteria (that is, CpG ≤ 1,000 bp from neighbors). DMR methylation level was defined as the mean β -value of all probes located in the DMR. Fibroblast DMRs are provided in Supplementary Tables 2 and 3. For RRBS data, DMRs were called using a binomial linear model to test for a difference in the proportion of methylated reads for each CpG in the homozygous mutant samples versus controls. CpGs showing significant differences were then identified as those with Benjami-Hochberg adjusted P < 0.05. DMRs were then called in a manner similar to that used for the Infinium arrays but using a distance threshold of 200 bp. A control set of CpG sites that were within the distance threshold was used as a background control set of 'all' CpGs for enrichment analyses. Only CpGs where coverage was ≥ 10 in all samples were considered for DMR calling (1,516,046 CpGs). For RRBS, DMR methylation level was defined as the weighted mean methylation level (methylated coverage/total coverage) from all CpGs observed within the DMR region irrespective of coverage. NPC DMRs are provided in Supplementary Tables 5 and 10 .
Enrichment of DMRs in ChromHMM segmentations. Infinium probes were mapped to existing ChromHMM annotations 70 using the BEDtools intersect function (version 2.27.1) 71 . Identical ChromHMM labels were merged for analysis. To test for enrichment of an annotation, a Fisher's exact test was performed for number of DMR probes against number of control probes.
DNA methylation valley analysis. Previously reported DMVs 26 were mapped to hg19 using the University of California Santa Cruz liftover tool and merged DMV regions from all five cell types determined using the Bedtools merge function. DMV methylation level was defined as mean β -value of all probes present in the DMV. DMVs were then mapped to their closest genes using ChIPpeakAnno (for details, see Supplementary Note). Using DMR and control gene lists (as defined in gene ontology analysis section, see Supplementary Note), DMR enrichment at DMVs was tested by Fisher's exact test, comparing the proportion of DMRassociated genes that were DMV genes with the proportion of control genes that were DMV genes.
Analysis of histone modifications at DMRs, DMVs and ChIP-seq peaks. Nonoverlapping windows of 250 bp (for DMRs and ChIP-seq peaks) or 500 bp (for DMVs) were defined centered on each region of interest, with ChIP-seq read counts per window calculated using BEDtools' coverage function. Read counts were scaled to counts per 10 million based on total number of mapped reads per sample and divided by the input read count to provide normalized read counts. To prevent windows with zero reads in the input sample generating a normalized count of infinity, an offset of 0.5 was added to all windows before scaling and input normalization. Regions where coverage was 0 in all samples were removed from the analysis. ChIP-Rx was analyzed similarly before samples were scaled using a normalization factor generated from the number of reads mapping to the spike-in D. melanogaster genome. Reads mapping to the D. melanogaster genome in each ChIP and input sample were first scaled to reads per 1 × 10 7 . The scaling factor was then calculated as the ratio of the scaled D. melanogaster reads in two ChIP samples over their respective ratio from the input samples; that is scaling factor, S, for sample n compared to reference sample ref:
for ChIP and input (IN) runs, respectively (modified from published method to take account of the presence of an input sample) 65 . To statistically test differences in histone modification levels, normalized read depths across DMRs and DMVs were compared using a Wilcoxon rank sum test. H3K27me3-marked DMVs were defined as those containing a H3K27me3 ChIP-seq peak replicated in both control fibroblast lines. H3K27me3 and H3K4me3 peaks used for quantitative analysis were defined by merging peaks called in the two controls (using Bedtools merge). Only autosomal peaks overlapping those called in both control samples and containing Infinium probes in the background control set from DMR calling were used for analysis. The subsets of these peaks overlapping DMRs were defined using Bedtools intersect. The change in histone modification levels within regions of interest was defined as the log 2 ratio of the mean mutant normalized read count over control normalized read count. The profile of H3K36me3 at DMVs was generated by calculating normalized read counts in ten scaled windows across DMVs together with 500-bp windows extending 10 kb upstream and downstream of each DMV. Color scales for ChIP-seq heatmaps range from the minimum to the 90% quantile of the normalized read count for the reference data set in each set of heatmaps.
Analysis of enrichment of histone modifications at DMRs. BEDtools intersect was used to overlap DMR probes with histone modification peaks. Percentage DMR probes mapping to peaks was tested against percentage background control probes mapping to peaks using a Fisher's exact test. A similar strategy was applied for mouse RRBS DMRs, testing DMR CpG versus background control CpG sites.
RNA-seq analysis.
To analyze RNA-seq data, the number of reads mapping to each ENSEMBL annotated gene (human, release 75/GCRh37; mouse, release 91/ mm10) was calculated using the featureCounts module of the subread aligner (version 1.5.2) 72 . Only reads mapping to exons were considered. Gene read counts were then analyzed using EdgeR (version 3.18.1) 73 with trimmed mean of M-values (TMM) normalization 74 . The log 2 normalized counts per million (CPM) and log 2 ratios calculated by EdgeR were then subjected to further analysis. Only genes where CPM was > 1 in ≥ 2 samples and that were annotated as protein coding in ENSEMBL were considered for analysis (human fibroblasts, 11,963 genes; mouse NPCs, 13,022 genes). To generate lists of genes differentially regulated in published data of mESCs differentiated to terminally differentiated neurons 38 , similar preprocessing was applied (resulting in data for 14,780 genes). Differential expression was then called using an F-test of a generalized linear model fitted to the data taking account of sample batch using EdgeR. Upregulated and downregulated genes were called as those with Benjamini-Hochberg corrected FDR < 0.01 and a log 2 -fold change > |1| (4,147 and 4,067 genes, respectively). Genes unchanged in the analysis were defined as those with Benjamini-Hochberg corrected FDR > 0.05 (4,067 genes).
Accession codes. DNMT3A, NM_175629.2.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Sample size
For most experiments, no statistical method was used to pre-determine sample size. Sample size was chosen based on standard practices in the field. Sequencing depth for RRBS of the NPC differentiation was determined by a power calculation.
Data exclusions No data was excluded.
Replication
All attempts at replication were successful. Independent experiments were performed to ensure reproducibility as documented in Figure  legends and methods.
Randomization No methods of randomization were used. Samples/organisms/participants allocated to groups on basis of genotypes (i.e. mendelian randomization for organisms and participants).
Blinding
Investigators were blinded for the collection of mouse body and brain weight data. The investigators were not blinded for other cell biology experiments as objective outcome measures (e.g. band present or absent on immunoblot) were used.
